Skip to content

Lexeo Therapeutics, Inc.

LXEO

CIK 0001907108

← back to feed
Revenue (TTM)
$654K
Q1 May 2026
Net Income (TTM)
−$99.24M
−1.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.17
+39.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-16,586.2%
Q1 May 2026
Net Margin
-15,174.0%
Q1 May 2026
Free Cash Flow (TTM)
−$76.5M
Q1 May 2026
Cash
$71.77M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
78.52M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings